|
|
Article: Celgene Corporation Provides Product and Pipeline Update; Financial Guidance Reaffirmed THALOMID(R) Growth Drivers Reviewed New Class of Anti-Cancer Tubulin Inhibitors Discovered Acceleration of Pipeline Highlighted Placental Stem Cell Strategies and Synergies Outlined.
- Article from:
- PR Newswire
- Article date:
- March 7, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Celgene Corporation provided an overview of recent developments including highlights from its extensive research and development pipeline at the Company's Analyst and Investor Meeting yesterday in New York City. Presentations by Celgene management and scientists discussing the progress of the Company's products and programs were augmented by presentations by leading scientific and clinical collaborators. The meeting was webcast live on the internet and the entire replay of the event can be accessed in the Investor Relations section of the Company's website at http://www.celgene.com.
"Yesterday's meeting was an outstanding opportunity for our team to outline the ...